Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuvonralimab/Iparomlimab plus paclitaxel for second-line advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2600128548Phase 4Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital, South China University of Technology
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tuvonralimab, iparomlimab and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The Sixth Affiliated Hospital, South China University of Technology. Primary endpoint: Progression-Free Survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tuvonralimabiparomlimabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600128548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128548.